Jonathan Wang, PhD

Dr. Jonathan Wang is the Chairman, and CEO of Miragene, with more than 30 years of experience in healthcare and life sciences across entrepreneurship, investment, and research.

He previously founded and led Inmagene as Chairman and CEO, guiding the company through a reverse merger to form ImageneBio (NASDAQ: IMA). Earlier in his career, Dr. Wang spent 22 years in healthcare investing, including 12 years as a partner at OrbiMed and as a founding partner of OrbiMed Asia, where he and his partners established and managed $1.1 billion in private equity and venture capital funds.

Dr. Wang has served on numerous boards, including ImageneBio, InventisBio (688382.SS), Laekna (2105.HK), AngelAlign (06699.HK), Genwiz (acquired), and ForteBio (acquired). He has also helped create several ventures, such as Celexor Bio and Bridge Laboratories (acquired), and served as a member of the Biotech Advisory Board of the Hong Kong Stock Exchange.

He earned his PhD in neurobiology from Columbia University under Nobel Laureate Dr. Eric Kandel and holds an MBA from Stanford University. Beyond business and science, Dr. Wang co-founded and served as the founding Chairman of The BayHelix Group and is the author of two books on the philosophy of science.